Phase II Randomized Trial of XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients - IMMUNOSTAR Trial GOIRC-02-2024
Latest Information Update: 06 Feb 2026
At a glance
- Drugs Dostarlimab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms IMMUNOSTAR
Most Recent Events
- 12 Nov 2025 New trial record